Article

Oral etoposide and trastuzumab in HER2-positive metastatic breast cancer: a retrospective study at Institut Curie Hospitals.

2022-02-17

Abstract excerpt

<h4>Background: </h4> The TOP2A and ERBB2 genes are co-amplified in about 40% of HER2 positive (HER2+) breast cancers. Oral etoposide (VP16), an inhibitor of topoisomerase-II (encoded by TOP2A ), has demonstrated clinical activity in metastatic breast cancer (MBC). However, the clinical benefit of oral VP16 combined with trastuzumab (VP16-T) in HER2+ MBC has not been evaluated. <h4>Methods: </h4>: Patients treated...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 0e29a534-5a1d-52d5-821e-d4b6c41f2002
DOI: 10.21203/rs.3.rs-1325343/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Oral etoposide and trastuzumab in HER2-positive metastatic breast cancer: a retrospective study at Institut Curie Hospitals.DOI 10.21203/rs.3.rs-1325343/v1Read

Real-World Outcomes of CDK4/6 Inhibitors in Germline BRCA-Mutated Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: Turkish Oncology Group (TOG) StudySemantic proximity Read

Comparison of Targeted Therapy Efficacy in HER2-Positive Versus HER2-Negative Breast Cancer PatientsSemantic proximity Read

Efficacy and Safety of the use of Pertuzumab in Metastatic Breast Cancer Patients in a Real-World Setting: Results from the SUPER-GONO (Gruppo Oncologico del Nord Ovest) StudySemantic proximity Read

Clinical and molecular characterization of the vinorelbine-platinum chemotherapeutic regimen in HER2(-) metastatic breast cancerSemantic proximity Read

Anthracycline-Free Neoadjuvant Treatment in Patients with HER2-Positive Breast Cancer: Real-Life Use of Pertuzumab, Trastuzumab and Taxanes Association with an Exploratory Analysis of PIK3CA Mutational StatusSemantic proximity Read

BRCA1/2 Mutations and Efficacy of Pembrolizumab-Based Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer: A Real-World Multicenter AnalysisSemantic proximity Read

Clinical characteristics and treatment outcomes of HER2 mutation and HER2 fusion in 22 patients with advanced breast cancer.Semantic proximity Read

ctDNA Analysis in ERBB2 -Amplified Colorectal Cancer: Biomarker Analysis of the MyPathway TrialSemantic proximity Read

NSABP FB-10: a phase Ib/II trial evaluating ado-trastuzumab emtansine (T-DM1) with neratinib in women with metastatic HER2-positive breast cancer.Semantic proximity Read

Concurrent Mutations Associated With Trastuzumab-resistance Revealed by Single Cell SequencingSemantic proximity Read

First-line pembrolizumab, trastuzumab, and chemotherapy in advanced HER2-positive gastric cancer with sequential genomic profilingSemantic proximity Read

Single HER2-Positive Tumor Cells are Detected in Initially HER2-Negative Breast Carcinomas using the DEPArray™–HER2-FISH WorkflowSemantic proximity Read